Agenda: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach
EBAC accredited symposium held during Heart Failure 2017, Paris
Monday, May 1, 2017
- Introduction -Adriaan Voors, MD, UMCG, Groningen, The Netherlands
- Challenges in Heart Failure management: Diabetes and Renal Impairment - Prof. Martin Cowie, Imperial College London, London, United Kingdom
- SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome - Prof. Per-Henrik Groop, University of Helsinki, Helsinki, Finland
- New diabetes drugs and heart failure: What have we learnt? - Prof. John McMurray, University of Glasgow, United Kingdom
The Educational objectives were
- Emphasize heart failure as a disease in which innovation is ongoing, yielding several new agents that are soon likely to change clinical practice
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
- To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events
This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities
Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.